Novel pharmacotherapies and breakthroughs in psoriasis treatment: 2024 and beyond

ABSTRACT

Introduction

The use of the current available therapies for psoriasis management may sometimes be limited by reduced patients’ compliance, safety issues for patients’ comorbidities, primary lack of efficacy, loss of effectiveness, development of side effects. In this context, several clinical trials investigating the use of both topical and systemic therapies are ongoing, and other new drugs will be approved soon.

Areas covered

The aim of this manuscript is to review current literature and to provide an overview of the current and future trends in psoriasis treatment. A comprehensive review of the English-language medical literature was performed using Pubmed and clinicaltrials.gov databases.

Expert opinion

Although several therapies are currently available for psoriasis’ treatment, unmet needs still exist for patients with moderate and severe psoriasis and hence expanding the therapeutic armamentarium is desirable for a more personalized approach. The ongoing development of innovative therapies could provide effective and safe therapies in the future enhancing the therapeutic management of moderate-severe unresponsive psoriasis.

KEYWORDS:

• Psoriasis
• management
• new treatments
• systemic treatments
• biologics

Article highlights

• Although several therapies are currently available for psoriasis’ treatment, unmet needs still exist for patients with moderate and severe psoriasis and hence expanding the therapeutic armamentarium is desirable for a more personalized approach.

• The aim of this manuscript is to review current literature to provide an overview of the current and future trends in psoriasis treatment.

• The ongoing development of innovative therapies could provide effective and safe therapies in the future enhancing the therapeutic management of moderate-severe unresponsive psoriasis.

• The availability of several drugs is beneficial for personalized and precision medicine.

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Data availability statement

The authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary materials.

Author contribution

A Portarapillo: data curation, formal analysis, investigation, visualization, writing-original draft preparation, writing – review & editing. L Potestio: data curation, formal analysis, investigation, visualization, writing-original draft preparation, writing – review & editing. N Tommasino: data curation, formal analysis, investigation, visualization, writing-original draft preparation, writing – review & editing. G Lauletta: data curation, formal analysis, investigation, visualization, writing-original draft preparation, writing – review & editing. F Feo: data curation, formal analysis, investigation, visualization, writing-original draft preparation, writing – review & editing. A Salsano: data curation, formal analysis, investigation, visualization, writing-original draft preparation, writing – review & editing. F Martora: data curation, formal analysis, investigation, visualization, writing-original draft preparation, writing – review & editing. F Caso: data curation, formal analysis, investigation, visualization, writing-original draft preparation, writing – review & editing. M Megna: data curation, formal analysis, investigation, visualization, writing-original draft preparation, writing – review & editing. All authors read and approved the final version of the manuscript.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper was not funded.